{"id":"W1997880566","doi":"10.1016/s1474-4422(14)70068-7","title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","year":2014,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":395,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"IC Design Education Center; Biogen","keywords":"Medicine; Placebo; Multiple sclerosis; Internal medicine; Clinical endpoint; Expanded Disability Status Scale; Relapsing remitting; Adverse effect; Gastroenterology; Dosing; Pegylated interferon; Randomized controlled trial; Immunology; Ribavirin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002322215,0.0003568041,0.001256177,0.0001621298,0.000464991,0.00004873684,0.0004840054,0.0001349187,0.00004054014],"category_scores_gemma":[0.002122164,0.0002355473,0.0002272179,0.0002847072,0.000323496,0.00009512847,0.0003085938,0.0008227789,0.00004116845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003765034,"about_ca_system_score_gemma":0.00003683485,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006687362,"about_ca_topic_score_gemma":0.0001429752,"domain_scores_codex":[0.9966705,0.000633356,0.0006436146,0.0007151335,0.0003781269,0.000959203],"domain_scores_gemma":[0.9953055,0.002994192,0.000263147,0.001010246,0.0002584404,0.0001684698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.856119,0.002199697,0.02504936,0.0002062838,0.0008695672,0.00001851742,0.003057853,0.0002715876,0.05953518,0.00007916056,0.006807967,0.0457858],"study_design_scores_gemma":[0.9162304,0.01604257,0.02299526,0.0001465667,0.0005647594,0.00004642621,0.0003457498,0.02136628,0.004936564,0.00009701408,0.01677684,0.0004516039],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792889,0.0002502356,0.001504466,0.0119278,0.0005016752,0.005502633,0.00002034855,0.0002204428,0.0007834426],"genre_scores_gemma":[0.9949181,0.00020333,0.0003890334,0.001961331,0.001189186,0.001060554,0.00002884419,0.00007517494,0.0001744434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06011133,"threshold_uncertainty_score":0.9605339,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1893065369257501,"score_gpt":0.385908890795452,"score_spread":0.1966023538697019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}